Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Therapeutic Antibodies

Therapeutic Antibodies

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
A293 BMS patent anti-Integrin α5β1 Biosimilar(Anti-Integrin a5b1 (ITGA5 & ITGB1) Reference Antibody) Featured
A226 Eblasakimab Biosimilar(Anti-IL-13Ra1 / CD213a1 Reference Antibod) Featured
Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells.
More description
A1061 Osemitamab Biosimilar(Anti-CLDN18.2 Reference Antibody) Featured
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study.
More description
A736 Ivonescimab Biosimilar Featured
Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research.
More description
A1060 Muromonab Biosimilar(Anti-CD3 Reference Antibody) Featured
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection.
More description
A1059 Atoltivimab Biosimilar(Anti-EBOV Reference Antibody) Featured
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection.
More description
A1058 Navivumab Biosimilar(Anti-HA Reference Antibody) Featured
Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2.
More description
A1057 Anti-IAV Reference Antibody Biosimilar Featured
A1056 Odesivimab Biosimilar(Anti-Zaire Ebola virus Reference Antibody) Featured
Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection.
More description
A1055 Cosfroviximab Biosimilar(Anti-Zaire Ebola virus Reference Antibody) Featured
Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP).
More description
A1054 Porgaviximab Biosimilar(Anti-Zaire Ebola virus Reference Antibody) Featured
Porgaviximab is a monoclonal antibody that can be used Ebola infection research.
More description
A1053 Larcaviximab Biosimilar(Anti-Zaire Ebola virus Reference Antibody) Featured
Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody.
More description
A1052 Romlusevimab Biosimilar(Anti-Spike RBD Reference Antibody) Featured
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
More description
A1051 Cilgavimab Biosimilar(Anti-Spike RBD Reference Antibody) Featured
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection.
More description
A1050 Regdanvimab Biosimilar(Anti-Spike RBD Reference Antibody) Featured
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19.
More description
A1049 Tixagevimab Biosimilar(Anti-Spike RBD Reference Antibody) Featured
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor.
More description
A1048 Etesevimab Biosimilar(Anti-Spike RBD Reference Antibody) Featured
Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody.
More description
A1047 Sotrovimab Biosimilar(Anti-Spike RBD Reference Antibody) Featured
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease.
More description
A1046 Amubarvimab Biosimilar(Anti-Spike RBD Reference Antibody) Featured
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants.
More description
A1045 Semzuvolimab Biosimilar(Anti-CD4 Reference Antibody) Featured
Semzuvolimab is a murine IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Murine CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection.
More description
A1044 Temtokibart Biosimilar(Anti-IL22RA1 Reference Antibody) Featured
Temtokibart is a humanized IgG1λ2 antibody targeting IL22RA1. Expressed by cells lacking the glutamine synthetase gene.
More description
A1043 Maftivimab Biosimilar(Anti-Zaire ebolavirus Reference Antibody) Featured
Maftivimab (REGN3470-3471-3479), the inhibitor of Filovirus, is an Food and agent Administration (FDA)-approved agent. Maftivimab, also named as Atoltivimab, Odesivimab (Inmazeb), can be used for research of Zaire ebolavirus infection.
More description
A1042 Ansuvimab Biosimilar(Anti-Zaire ebolavirus Reference Antibody) Featured
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells.
More description
A1041 Iluzanebart Biosimilar(Anti-TREM2 Reference Antibody) Featured
Iluzanebart is a human IgG1κ antibody targeting TREM2, a triggering receptor expressed on myeloid cells.
More description
A1040 Burfiralimab Biosimilar(Anti-Vimentin Reference Antibody) Featured
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies.
More description
A1039 Dalnicastobart Biosimilar(Anti-TNFRSF5 / CD40 Reference Antibody) Featured
Dalnicastobart (LVGN-7409) is a human IgG1κ antibody targeting CD40/TNFRSF5.
More description
A1038 Stapokibart Biosimilar(Anti-IL-4Ra / CD124 Reference Antibody) Featured
Stapokibart (CM310) is a humanised monoclonal antibody targeting IL-4Rα and efficiently blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart has the capacity to interact with IL-4Rα in humans, cynomolgus monkeys, and rats.
More description
A1037 Raludotatug Biosimilar(Anti-CDH6 / K-Cadherin Reference Antibody) Featured
Raludotatug is a humanized immunoglobulin G1-kappa, anti-CDH6 monoclonal antibody. Raludotatug is an antineoplastic.
More description
A1036 Izeltabart Biosimilar(Anti-ADAM9 Reference Antibody) Featured
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models.
More description
A1035 Keliximab Biosimilar(Anti-CD4 Reference Antibody) Featured
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research.
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X